ATE456953T1 - Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga - Google Patents
Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analogaInfo
- Publication number
- ATE456953T1 ATE456953T1 AT06736552T AT06736552T ATE456953T1 AT E456953 T1 ATE456953 T1 AT E456953T1 AT 06736552 T AT06736552 T AT 06736552T AT 06736552 T AT06736552 T AT 06736552T AT E456953 T1 ATE456953 T1 AT E456953T1
- Authority
- AT
- Austria
- Prior art keywords
- pyrimethamine
- analogs
- treatment
- lateral sclerosis
- amyotrophic lateral
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 title 1
- 229960000611 pyrimethamine Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000001243 protein synthesis Methods 0.000 abstract 2
- 230000014616 translation Effects 0.000 abstract 2
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 abstract 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 210000000663 muscle cell Anatomy 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Polyurethanes Or Polyureas (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65850505P | 2005-03-04 | 2005-03-04 | |
| PCT/US2006/007257 WO2006096405A2 (en) | 2005-03-04 | 2006-03-01 | Treatment of amyotrophic lateral sclerosis with pyrimethamine and analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE456953T1 true ATE456953T1 (de) | 2010-02-15 |
Family
ID=36953835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06736552T ATE456953T1 (de) | 2005-03-04 | 2006-03-01 | Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060211645A1 (https=) |
| EP (1) | EP1917017B1 (https=) |
| JP (1) | JP2008531710A (https=) |
| CN (1) | CN101184493A (https=) |
| AT (1) | ATE456953T1 (https=) |
| AU (1) | AU2006220919A1 (https=) |
| CA (1) | CA2600067A1 (https=) |
| DE (1) | DE602006012115D1 (https=) |
| ES (1) | ES2340708T3 (https=) |
| WO (1) | WO2006096405A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060205704A1 (en) * | 2005-03-04 | 2006-09-14 | Alsgen, Llc | Modulation of neurodegenerative diseases through the progesterone receptor |
| WO2006096415A2 (en) * | 2005-03-04 | 2006-09-14 | Alsgen, Llc | Modulation of neurodegenerative diseases through the estrogen receptor |
| US20070135437A1 (en) * | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
| US20080153094A1 (en) * | 2006-10-13 | 2008-06-26 | Minor James M | Reduction of nonspecific binding in nucleic acid assays and nucleic acid synthesis reactions |
| US20110092554A1 (en) * | 2007-11-19 | 2011-04-21 | Richard Chesworth | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders |
| WO2009086277A1 (en) | 2007-12-20 | 2009-07-09 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
| EP2432776B1 (en) * | 2009-05-21 | 2019-09-11 | Universite Laval | Methyl sulfanyl pyrimidines useful as antiinflammatories, analgesics, and antiepileptics |
| GB201015079D0 (en) | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
| MX354412B (es) | 2011-06-10 | 2018-03-05 | Merck Patent Gmbh | Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton. |
| CN104398517A (zh) * | 2014-11-28 | 2015-03-11 | 四川大学 | 乙胺嘧啶的新用途及治疗肿瘤的药物组合物 |
| WO2021096199A1 (ko) * | 2019-11-11 | 2021-05-20 | 에스케이케미칼 주식회사 | 피리메타민을 유효성분으로 포함하는 면역 관련 질환의 치료 또는 예방용 약학 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231170A (en) * | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
| US5866562A (en) * | 1996-10-25 | 1999-02-02 | Bayer Aktiengesellschaft | Ring-bridged bis-quinolines |
| US7442629B2 (en) * | 2004-09-24 | 2008-10-28 | President & Fellows Of Harvard College | Femtosecond laser-induced formation of submicrometer spikes on a semiconductor substrate |
| KR101031720B1 (ko) * | 2001-11-28 | 2011-04-29 | 비티지 인터내셔널 리미티드 | 질소함유 헤테로아릴 화합물을 함유하는 알츠하이머병의예방약 또는 치료약 또는 아밀로이드 단백질 섬유화억제제 |
| MXPA04008901A (es) * | 2002-03-13 | 2004-11-26 | Euro Celtique Sa | Pirimidinas arilo sustituidas y el uso de las mismas. |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US20060205704A1 (en) * | 2005-03-04 | 2006-09-14 | Alsgen, Llc | Modulation of neurodegenerative diseases through the progesterone receptor |
| US20070135437A1 (en) * | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
-
2006
- 2006-03-01 EP EP06736552A patent/EP1917017B1/en not_active Expired - Lifetime
- 2006-03-01 US US11/365,462 patent/US20060211645A1/en not_active Abandoned
- 2006-03-01 DE DE602006012115T patent/DE602006012115D1/de not_active Expired - Lifetime
- 2006-03-01 AT AT06736552T patent/ATE456953T1/de not_active IP Right Cessation
- 2006-03-01 WO PCT/US2006/007257 patent/WO2006096405A2/en not_active Ceased
- 2006-03-01 JP JP2007558177A patent/JP2008531710A/ja active Pending
- 2006-03-01 CN CNA2006800153119A patent/CN101184493A/zh active Pending
- 2006-03-01 AU AU2006220919A patent/AU2006220919A1/en not_active Abandoned
- 2006-03-01 ES ES06736552T patent/ES2340708T3/es not_active Expired - Lifetime
- 2006-03-01 CA CA002600067A patent/CA2600067A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060211645A1 (en) | 2006-09-21 |
| AU2006220919A1 (en) | 2006-09-14 |
| WO2006096405A8 (en) | 2008-04-10 |
| DE602006012115D1 (de) | 2010-03-25 |
| EP1917017A2 (en) | 2008-05-07 |
| ES2340708T3 (es) | 2010-06-08 |
| CN101184493A (zh) | 2008-05-21 |
| EP1917017B1 (en) | 2010-02-03 |
| JP2008531710A (ja) | 2008-08-14 |
| WO2006096405A3 (en) | 2007-05-18 |
| WO2006096405A2 (en) | 2006-09-14 |
| CA2600067A1 (en) | 2006-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
| TW200612905A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| TW200531689A (en) | Therapeutic agents | |
| WO2008067389A3 (en) | Modulation of sod protein synthesis for the treatment of neurodegenerative diseases | |
| EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
| MY147767A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| ECSP066336A (es) | Derivados de 3-amino croman y 2-amino tetralin | |
| UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
| DE602007012473D1 (de) | Als proteinkinaseinhibitoren geeignete verbindungen | |
| BR0208150A (pt) | Antagonistas de mch e sua aplicação no tratamento da obesidade | |
| EA200700175A1 (ru) | Композиции и способы лечения воспалительных заболеваний | |
| BRPI0519124A2 (pt) | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço | |
| NO20054905L (no) | 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika | |
| EP1505990A4 (en) | METHOD FOR THE TREATMENT OF HEPATITIS | |
| EA200602243A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
| GB0625648D0 (en) | Compounds | |
| ATE491446T1 (de) | Ligustilid zur behandlung von erkrankungen des zentralen nervensystems | |
| ECSP055964A (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
| TW200635903A (en) | Therapeutic agents | |
| TW200714277A (en) | Methods and compositions for altering cell fuction | |
| MXPA06012500A (es) | Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo. | |
| ATE456953T1 (de) | Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga | |
| TW200611695A (en) | Pyrrolopyridine derivatives | |
| ATE433966T1 (de) | Methylendipiperidinderivate | |
| BRPI0506970B8 (pt) | derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |